MACC1 promotes pancreatic cancer metastasis by interacting with the EMT regulator SNAI1 DOI Creative Commons

Xianglian Zhang,

Ya Luo,

Yu Cen

et al.

Cell Death and Disease, Journal Year: 2022, Volume and Issue: 13(11)

Published: Nov. 4, 2022

Metastasis is the dominant cause of cancer-related mortality. Metastasis-associated with colon cancer protein 1 (MACC1) has been proven to play a critical role in metastasis. However, prometastatic MACC1 regulating pancreatic (PC) metastatic phenotype remains elusive. Here, we report that highly expressed The Cancer Genome Atlas (TCGA) and tissue microarray (TMA) identified as good indicator for poor prognosis. Overexpression or knockdown PC cells correspondingly promoted inhibited cell migration invasion MET proto-oncogene receptor tyrosine kinase (MET)-independent manner. Notably, markedly decreased liver lesions metastasis model. Mechanistically, binds epithelial-mesenchymal transition (EMT) regulator snail family transcriptional repressor (SNAI1) drive EMT via upregulating activity SNAI1, leading transactivation fibronectin (FN1) trans-repression cadherin (CDH1). Collectively, our results unveil new mechanism by which drives suggest MACC1-SNAI1 complex-mediated mesenchymal may be therapeutic target cancer.

Language: Английский

SKP2 promotes the metastasis of pancreatic ductal adenocarcinoma by suppressing TRIM21-mediated PSPC1 degradation DOI
J. Yuan, Zeyao Zhu, Ping Zhang

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 587, P. 216733 - 216733

Published: Feb. 14, 2024

Language: Английский

Citations

13
Comprehensive insights into pancreatic cancer treatment approaches and cutting-edge nanocarrier solutions: from pathology to nanomedicine DOI
Rohit Sharma, Sourabh Kumar,

Kumari Komal

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: April 9, 2025

Language: Английский

Citations

1
Circular RNA circ-MTHFD1L induces HR repair to promote gemcitabine resistance via the miR-615-3p/RPN6 axis in pancreatic ductal adenocarcinoma DOI Creative Commons
Zhi‐Wen Chen, Jianfei Hu,

Zuwei Wang

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2022, Volume and Issue: 41(1)

Published: April 23, 2022

Abstract Background Chemoresistance of pancreatic cancer is the main reason for poor treatment effect patients. Exploring chemotherapy resistance-related genes has been a difficult and hot topic oncology. Numerous studies implicate key roles circular RNAs (circRNAs) in development cancer. However, regulation circRNAs process ductal adenocarcinoma (PDAC) resistance not yet fully clear. Methods Based on cross-analysis Gene Expression Omnibus (GEO) database data our center, we explored new molecule, hsa_circ_0078297 (circ-MTHFD1L), related to resistance. QRT-PCR was used detect expression circRNAs, miRNAs, mRNAs human PDAC tissues their matched normal tissues. The interaction between circ-MTHFD1L miR-615-3p/RPN6 signal axis confirmed by series experiments such as Dual-luciferase reporter assay, fluorescence situ hybridization (FISH) RNA immunoprecipitation (RIP) assays. Results Circ-MTHFD1L significantly increased cells. And patients, higher level circ-MTHFD1L, worse prognosis. Mechanism analysis showed that an endogenous miR-615-3p sponge, upregulates RPN6, thereby promoting DNA damage repair exerting its enhancing gemcitabine More importantly, also found Silencing combined with olaparib can increase sensitivity gemcitabine. Conclusion maintains through axis. may be molecular marker effective PDAC.

Language: Английский

Citations

36
Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer DOI
Weifan Zhang, Weikun Qian, Jingtao Gu

et al.

Cancer Letters, Journal Year: 2022, Volume and Issue: 552, P. 215976 - 215976

Published: Oct. 20, 2022

Language: Английский

Citations

31
Exploration of tumor penetrating peptide iRGD as a potential strategy to enhance tumor penetration of cancer nanotherapeutics DOI
Mohd Aslam Saifi,

Gauri Sathish,

Mohd Rabi Bazaz

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2023, Volume and Issue: 1878(3), P. 188895 - 188895

Published: April 8, 2023

Language: Английский

Citations

22
Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma DOI Creative Commons
Andrea Vallés‐Martí, G. Mantini, Paul Manoukian

et al.

Cell Reports, Journal Year: 2023, Volume and Issue: 42(6), P. 112581 - 112581

Published: June 1, 2023

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with limited set of known driver mutations but considerable cancer cell heterogeneity. Phosphoproteomics provides readout aberrant signaling and has the potential to identify new targets guide treatment decisions. Using two-step sequential phosphopeptide enrichment, we generate comprehensive phosphoproteome proteome nine PDAC lines, encompassing more than 20,000 phosphosites on 5,763 phospho-proteins, including 316 protein kinases. By using integrative inferred kinase activity (INKA) scoring, multiple (parallel) activated kinases that are subsequently matched inhibitors. Compared high-dose single-drug treatments, INKA-tailored low-dose 3-drug combinations against demonstrate superior efficacy organoid cultures, patient-derived xenografts. Overall, this approach particularly effective aggressive mesenchymal model compared epithelial in both preclinical settings may contribute improved outcomes patients.

Language: Английский

Citations

18
Metastatic Pancreatic Cancer: Where Are We? DOI Creative Commons
Abraham Hernández-Blanquisett, Valeria Quintero-Carreño, María Cristina Martínez‐Ávila

et al.

Oncology Reviews, Journal Year: 2024, Volume and Issue: 17

Published: Jan. 18, 2024

Pancreatic cancer is one of the most lethal neoplasms worldwide; it aggressive in nature and has a poor prognosis. The overall survival rate for pancreatic low. Most patients present non-specific symptoms advanced stages, which generally leads to late diagnosis, at point there no option curative surgery. treatment metastatic includes systemic therapy, some cases radiotherapy, more recently, molecular targeted therapies, can positively impact control improve quality life. This review provides an overview landscape based on recent literature, as well current options with cancer.

Language: Английский

Citations

7
Exploiting Nanotechnology for Drug Delivery: Advancing the Anti-Cancer Effects of Autophagy-Modulating Compounds in Traditional Chinese Medicine DOI Creative Commons
Zixian Liu, Tianming Lu,

Ruoning Qian

et al.

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 2507 - 2528

Published: March 1, 2024

Background: Cancer continues to be a prominent issue in the field of medicine, as demonstrated by recent studies emphasizing significant role autophagy development cancer. Traditional Chinese Medicine (TCM) provides variety anti-tumor agents capable regulating autophagy. However, clinical application autophagy-modulating compounds derived from TCM is impeded their restricted water solubility and bioavailability. To overcome this challenge, utilization nanotechnology has been suggested potential solution. Nonetheless, current body literature on nanoparticles delivering TCM-derived for cancer treatment limited, lacking comprehensive summaries detailed descriptions. Methods: Up November 2023, research study was conducted gather relevant data using databases, including PubMed, ScienceDirect, Springer Link, Web Science, CNKI. The keywords utilized investigation included "autophagy", "nanoparticles", "traditional medicine" "anticancer". Results: This review analysis overcoming delivery challenges enhancing anti-cancer properties TCM. evaluation based synthesis different classes TCM, mechanisms action treatment, benefits reported various scholarly sources. findings indicate that shows availability thereby opening up plethora therapeutic avenues. Conclusion: Nanotechnology enhance efficacy traditional through regulation Keywords: autophagy, nano-delivery, anti-cancer, medicine

Language: Английский

Citations

7
Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial DOI Creative Commons
Jiujie Cui, Shukui Qin, Yuhong Zhou

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Sept. 19, 2024

Abstract Liposomal irinotecan has shown promising antitumor activity in patients with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) who have undergone prior gemcitabine-based therapies. This randomized, double-blind, parallel-controlled, multicenter phase 3 study (NCT05074589) assessed the efficacy and safety of liposomal HR070803 combined 5-fluorouracil (5-FU) leucovorin (LV) this patient population. Patients unresectable, locally advanced, PDAC had previously received therapies were randomized 1:1 to receive either (60 mg/m 2 anhydrous hydrochloride, equal 56.5 free base) placebo, both combination 5-FU (2000 ) LV (200 ), all given intravenously every two weeks. The primary endpoint was overall survival (OS). A total 298 enrolled plus 5-FU/LV (HR070803 group, n = 149) placebo (placebo 149). Median OS significantly improved group compared (7.4 months [95% CI 6.1–8.4] versus 5.0 4.3–6.0]; HR 0.63 0.48–0.84]; two-sided p 0.0019). most common grade ≥ adverse events increased gamma-glutamyltransferase (19.0% 11.6% group) decreased neutrophil count (12.9% 0 group). No treatment-related deaths occurred while reported one death (abdominal infection). manageable second-line setting, representing a potential option

Language: Английский

Citations

7
Surgical Treatment of Pancreatic Ductal Adenocarcinoma DOI Open Access
Kongyuan Wei, Thilo Hackert

Cancers, Journal Year: 2021, Volume and Issue: 13(8), P. 1971 - 1971

Published: April 20, 2021

Pancreatic ductal adenocarcinoma (PDAC) represents an aggressive tumor of the digestive system with still low five-year survival less than 10%. Although there are improvements for multimodal therapy PDAC, surgery remains effective way to treat disease. Combined adjuvant and/or neoadjuvant treatment, pancreatic is able enhance up around 20%. However, resection always associated a high risk complications and regarded as one most complex fields in abdominal surgery. This review gives summary on surgical treatment PDAC based current literature special focus techniques.

Language: Английский

Citations

34